@article{2724dc77bf6f4205a183749f0478367e,
title = "A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect",
abstract = "The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.",
keywords = "CTLA-4, aptamer, cancer, immunotherapy",
author = "Huang, {Bo Tsang} and Lai, {Wei Yun} and Chang, {Yi Chung} and Wang, {Jen Wei} and Yeh, {Shauh Der} and Lin, {Emily Pei Ying} and Yang, {Pan Chyr}",
note = "Funding Information: We dedicate this work to Dr. Konan Peck, a respected researcher in the fields of high-throughput biotechnology, biophysics, and cancer genomics. Shortly after initiating this project, Dr. Peck unfortunately succumbed to a rapidly progressing cancer. It is our fervent hope that the research platform established by Dr. Peck will result in the development of new diagnostic and therapeutic options that benefit cancer patients. We also thank the National Center for Genome Medicine for the technical and bioinformatics support. This project was supported by grants from the National Science Council ( NSC99-2320-B-001-012-MY3 and MOST104-2314-B-002-228-MY3 ). ",
year = "2017",
month = sep,
day = "15",
doi = "10.1016/j.omtn.2017.08.006",
language = "English",
volume = "8",
pages = "520--528",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",
}
